Sign in
CompletedNo phase

Stellate Ganglion Block in Herpes Zoster

Key facts

Who runs it
Tanta University
Where
Egypt3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
208 people enrolled
Started
1 May 2020
Ended
2 Feb 2025
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • Stellate ganglion block
  • Sham Stellate ganglion block
Record updated
13 February 2025

Who can take part

Age
60 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Patients who is presented to the pain clinic, diagnosed with acute herpes zoster of the face and/ or neck with onset of vesicular eruption less than seven days

Who cannot take part

  • Known history of allergy to local anesthetics
  • Local infection at the site of the block
  • Platelet count less than 75,000/ cc
  • Patient refusal or un-cooperation
  • Neurological deficit in the upper limb
  • Glaucoma
  • Bradycardia

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Patient who will be presented to Tanta University Hospitals complaining of acute herpes zoster with onset of vesicular eruption less than 7 days will be included in this clinical study.

Read full original descriptionShow less

Patients will be excluded if they refused participation, had allergy to local anesthetics, coagulopathy, local infection, glaucoma, or neurological deficit.

All the patients will receive acyclovir (antiviral therapy) and pregablin (analgesic) and the patients will be classified into two groups:- Group I (control group): Patients will receive sham block weekly for three times Group III (SGB group): Patients will receive stellate ganglion block weekly for three times

The time of first block after the onset of vesicular eruption, the incidence of PHN, NPRS at visit, duration of acute HZ , duration of PHN (if occurred), and the incidence of complication will be measured.

The 2 groups in the trial

  • Control group(Group I)Sham treatment, for comparison

    Patients will receive sham stellate ganglion block weekly for three times

    Treatment: Sham Stellate ganglion block

  • Stellate Ganglion block group (Group II)Treatment being tested

    Patients will receive stellate ganglion block weekly for three times with injection of 6ml bupivicain 0.25%+ 1 ml methylpredinosolone 40mg

    Treatment: Stellate ganglion block

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Utility of Early Serial Stellate Ganglion Block in Acute Herpes Zoster of Face and Neck
Record updated
13 February 2025